Basit öğe kaydını göster

dc.contributor.authorYasasever, Ceren
dc.contributor.authorDuranyildiz, Derya
dc.contributor.authorTas, Faruk
dc.contributor.authorKarabulut, Senem
dc.date.accessioned2021-03-05T11:48:41Z
dc.date.available2021-03-05T11:48:41Z
dc.date.issued2014
dc.identifier.citationTas F., Karabulut S., Yasasever C., Duranyildiz D., "Serum transforming growth factor-beta 1 (TGF-beta 1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma", TUMOR BIOLOGY, cilt.35, sa.7, ss.7233-7237, 2014
dc.identifier.issn1010-4283
dc.identifier.otherav_aa1163b4-4c63-4025-8e34-d36b439b7e7b
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/113558
dc.identifier.urihttps://doi.org/10.1007/s13277-014-1984-z
dc.description.abstractTransforming growth factor-beta 1 (TGF-beta 1) plays an important role in the pathogenesis of multiple malignancies, and its expression also strongly affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of TGF-beta 1 in melanoma patients. A total of 60 patients with a pathologically confirmed diagnosis of melanoma were enrolled into this study. Serum TGF-beta 1 concentrations were determined by the solid-phase sandwich ELISA method. Thirty age- and sex-matched healthy controls were included in the analysis. The median age at diagnosis was 53.5 years (range 16 to 88 years). The baseline serum TGF-beta 1 levels of the melanoma patients were significantly higher than those in the control group (median values 171.85 vs. 19.95 pg/mL, respectively; p 0.05). However, the chemotherapy-responsive patients had higher serum TGF-beta 1 levels compared with chemotherapy-unresponsive ones (p = 0.05). Additionally, serum TGF-beta 1 concentration was a trend to have a prognostic role on survival (p = 0.07). Patients with elevated serum TGF-beta 1 concentrations had close to significantly favorable overall survival compared to those with lower levels (median 30.1 vs. 20.9 months, respectively). In conclusion, serum levels of TGF-beta 1 have diagnostic, predictive, and possible prognostic roles in melanoma patients.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleSerum transforming growth factor-beta 1 (TGF-beta 1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma
dc.typeMakale
dc.relation.journalTUMOR BIOLOGY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume35
dc.identifier.issue7
dc.identifier.startpage7233
dc.identifier.endpage7237
dc.contributor.firstauthorID33396


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster